A review of clinical trials with fluoroquinolones with an emphasis on new agents (Q34074724)

30 July 2017

1 reference

title

A review of clinical trials with fluoroquinolones with an emphasis on new agents (English)

1 reference

30 July 2017

Blondeau JM

1

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 February 2000

1 reference

Expert Opinion on Investigational Drugs

30 July 2017

published in

1 reference

30 July 2017

volume

9

1 reference

30 July 2017

issue

2

1 reference

30 July 2017

page(s)

383-413

1 reference

In vitro antibacterial activity of AM-715, a new nalidixic acid analog

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

Antimicrobial-drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

Therapeutic advances of new fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

Urinary tract infections in females.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

Streptococcus pneumoniae resistant to penicillin and chloramphenicol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

Emergence of Multiply Resistant Pneumococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

INFLUENCE OF DAILY PENICILLIN, TETRACYCLINE, ERYTHROMYCIN, AND SULPHAMETHOXYPYRIDAZINE ON EXACERBATIONS OF BRONCHITIS. A REPORT TO THE RESEARCH COMMITTEE OF THE BRITISH TUBERCULOSIS ASSOCIATION.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

Results of the Alexander Project: a continuing, multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

Expanded activity and utility of the new fluoroquinolones: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

Antimicrobial resistance issues of the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

Urinary tract infections in women: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

Mechanism of fluoroquinolone action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

DNA topoisomerase targets of the fluoroquinolones: A strategy for avoiding bacterial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

Comparative tolerability of the newer fluoroquinolone antibacterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

Efficacy and Safety of a 10-Day Course of 400 or 600 Milligrams of Grepafloxacin Once Daily for Treatment of Acute Bacterial Exacerbations of Chronic Bronchitis: Comparison with a 10-Day Course of 500 Milligrams of Ciprofloxacin Twice Daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.9.2.383

21 January 2018

Identifiers

DOI

10.1517/13543784.9.2.383

1 reference

30 July 2017

1 reference